European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
Zawartość zarchiwizowana w dniu 2024-05-23

European action on anticoagulation (eaa): cost-effectiveness of computer-assisted dosage (eaa computer-dosage)

Cel

Oral Anticoagulant Treatment (OAT) is being used on an increasing scale in EU countries but steps are required to improve poor success of doctors in dosage as, even at specialised centres, patients are only maintained within therapeutic targets for about 50% of the time. Bleeding and thrombosis complications are associated with time "out of control" and labile control, both shown by an EC funded pilot study to be reduced by computer-dosage. A wide-ranging study sufficiently large to provide clinical end-points will be undertaken, to assess the extent to which computerised OAT dosage reduces thrombosis and haemorrhagic complications and is cost-effective. Cost-effectiveness from reduction of clinical complications and demands on medical manpower and administrative savings will be evaluated and the potential for increased provision of OAT within existing resources. Previously funded EC control materials will check conformity to WHO laboratory standards and treatment levels.

Dziedzina nauki

Program(-y)

Temat(-y)

Zaproszenie do składania wniosków

Data not available

System finansowania

CSC - Cost-sharing contracts

Koordynator

UNIVERSITY OF MANCHESTER
Wkład UE
Brak danych
Adres
Oxford Road
MANCHESTER
Zjednoczone Królestwo

Zobacz na mapie
Linki
Koszt całkowity
Brak danych

Uczestnicy (41)

Udostępnij tę stronę

Pobierz

Ostatnia aktualizacja: 12 Kwietnia 2005

Moja broszura

Permalink: https://cordis.europa.eu/project/id/QLG4-CT-2001-02175/pl

European Union, 2024